Galapagos Pivots to Business Development as Cell Therapy Wind-Down Begins
Event summary
- Galapagos reported €320.9 million net profit for 2025, up from €74.1 million in 2024, driven by a €1.07 billion revenue recognition from its Gilead collaboration.
- The company initiated the wind-down of its cell therapy activities in January 2026, expecting to complete the process by Q3 2026 with one-time restructuring costs of €125–175 million.
- GLPG3667, a TYK2 inhibitor, met its primary endpoint in dermatomyositis but failed to meet statistical significance in systemic lupus erythematosus.
- Galapagos expects to be cash flow neutral to positive by the end of 2026, with year-end cash of €2.775–2.850 billion.
The big picture
Galapagos is undergoing a strategic reset, shifting focus from internal R&D to external business development deals. The wind-down of its cell therapy unit and the recognition of deferred income from its Gilead collaboration highlight the company's pivot toward a leaner, more capital-efficient model. The success of this transition will depend on its ability to secure high-value partnerships and sustain its cash position.
What we're watching
- Business Development Strategy
- Whether Galapagos can successfully pivot to a business development-led growth model and identify transformative opportunities.
- Cash Position Management
- How the company will manage its cash position amid restructuring costs and potential business development activities.
- Clinical Pipeline Progress
- The pace at which Galapagos advances its TYK2 inhibitor program, particularly in dermatomyositis, and explores new autoimmune disease indications.
Related topics